A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells
- PMID: 10807502
- DOI: 10.1007/s000110050571
A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells
Abstract
Objective and design: We examined the effects of aceclofenac and its metabolites on the production of pro-collagenase-1/pro-matrix metalloproteinase-1 (proMMP-1), pro-gelatinase A/proMMP-2, pro-stromelysin-1/proMMP-3 and tissue inhibitor of metalloproteinases-1 (TIMP-1) by rheumatoid synovial cells.
Materials: Synovial cells were obtained from patients with rheumatoid arthritis.
Treatment: Cultures of confluent cells were treated with interleukin-1beta (IL-1beta)(1 ng/ml) and/or test drugs (0.3-30 microM) for 48 h.
Methods: Production of proMMPs and TIMP-1 was monitored by Western blotting or gelatin zymography. Prostaglandin E2 (PGE2) was measured by an enzyme immunoassay.
Results: 4'-Hydroxy aceclofenac, a major metabolite of aceclofenac, down-regulated both basal and IL-1beta-induced production of proMMP-1 and proMMP-3 at a concentration sufficient to suppress PGE2 production without modulating proMMP-2 or TIMP-1, whereas aceclofenac itself had no marked effect on the production of proMMPs.
Conclusions: Down-regulation of proMMP-1 and proMMP-3 production by 4'-hydroxy aceclofenac may contribute to the therapeutic effect of aceclofenac on rheumatoid arthritis and osteoarthritis.
Similar articles
-
Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts.Inflamm Res. 1997 Aug;46(8):320-3. doi: 10.1007/s000110050194. Inflamm Res. 1997. PMID: 9297577
-
Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts.Arthritis Rheum. 2001 Sep;44(9):2193-200. doi: 10.1002/1529-0131(200109)44:9<2193::aid-art373>3.0.co;2-5. Arthritis Rheum. 2001. PMID: 11592385
-
Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.J Pharmacol Exp Ther. 1999 May;289(2):676-81. J Pharmacol Exp Ther. 1999. PMID: 10215639
-
The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis.Curr Opin Pharmacol. 2001 Jun;1(3):314-20. doi: 10.1016/s1471-4892(01)00055-8. Curr Opin Pharmacol. 2001. PMID: 11712757 Review.
-
Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis.Expert Opin Investig Drugs. 2000 Jul;9(7):1469-78. doi: 10.1517/13543784.9.7.1469. Expert Opin Investig Drugs. 2000. PMID: 11060752 Review.
Cited by
-
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease.Drugs. 2001;61(9):1351-78. doi: 10.2165/00003495-200161090-00012. Drugs. 2001. PMID: 11511027 Review.
-
Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.Biomed Res Int. 2013;2013:230805. doi: 10.1155/2013/230805. Epub 2013 Jun 19. Biomed Res Int. 2013. PMID: 23862137 Free PMC article. Review.
-
Pharmacokinetics of a new once-daily controlled-release formulation of aceclofenac in Korean healthy subjects compared with immediate-release aceclofenac and the effect of food: a randomized, open-label, three-period, crossover, single-centre study.Clin Drug Investig. 2012 Feb 1;32(2):111-9. doi: 10.2165/11596530-000000000-00000. Clin Drug Investig. 2012. PMID: 22149151 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous